March 2024: The Food and Drug Administration has granted approval for the use of nivolumab (Opdivo, Bristol-Myers Squibb Company) in conjunction with cisplatin and gemcitabine as the initial treatment for adult patients with unres..
Feb 2024: The Food and Drug Administration has sped up the approval process for two drugs, enfortumab vedotin-ejfv (Padcev, Astellas Pharma) and pembrolizumab (Keytruda, Merck). These drugs are meant to treat people with locally ..
Agasti 2021: I-Nivolumab (Opdivo, Bristol-Myers Squibb Co.) igunyazwe yi-Food and Drug Administration ukuze zelashwe i-adjuvant yeziguli ezine-urothelial carcinoma (UC) ezisengozini enkulu yokuphinda iphinde iphinde ilandele i-rad.
Agasti 2021: I-Enfortumab vedotin-ejfv (Padcev, Astellas Pharma US, Inc.), inhlanganisela ye-antibody eqondiswe ku-Nectin-4 kanye ne-microtubule inhibitor, igunyazwe i-Food and Drug Administration ezigulini ezikhulile ezine-adv yasendaweni.
Agasti 2021: I-Sacituzumab govitecan (Trodelvy, Immunomedics Inc.) yanikezwa ukugunyazwa okusheshayo yi-Food and Drug Administration ezigulini ezinomdlavuza wendawo othuthukile noma we-metastatic urothelial (mUC) owake wathola ngaphambilini.